sulindac and Joint-Diseases

Topics: Aged; Bone Diseases; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Indenes; Joint Diseases; Male; Mefenamic Acid; Sulindac

Topics: Adult; Blood Cell Count; Female; Humans; Indenes; Joint Diseases; Sulindac; Thrombocytopenia

Topics: Anemia, Aplastic; Bone Marrow; Erythroblasts; Female; Humans; Indenes; Joint Diseases; Middle Aged; Sulindac

Topics: Adult; Aged; Female; Hip Joint; Humans; Indenes; Joint Diseases; Knee Joint; Male; Metatarsophalangeal Joint; Middle Aged; Sacroiliac Joint; Sulindac

Experience in therapy with sulindac and S-adenosyl-L-methionine (SAMe) is reported. Sulindac is an indene derivative which is particularly indicated in degenerative skeletal diseases and is essentially free from the well-known side-effects of traditional analgesics. The results of therapy were good in 75%. SAMe is the most important methyl group donor and is consequently responsible for the methylation (inactivation) of histamine, upon which its antiphlogistic action is based. SAMe is also particularly involved in the transfer of sulfate groups in the body. Sulfur compounds are esentially involved in the synthesis of cartilage. The short-term trials with SAMe were altogether more favorable than the longterm trials, yet there was a longterm effect in about half the cases.

Topics: Drug Evaluation; Hip Joint; Humans; Joint Diseases; S-Adenosylmethionine; Sulindac

Topics: Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Ibuprofen; Indenes; Joint Diseases; Sulindac